Mateo de Acosta ADA, Marín RNM, Andino VNA, Beristain HJL

Idioma: Español
Referencias bibliográficas: 105
Paginas: 59-74
Archivo PDF: 133.15 Kb.

RESUMEN

La infección pediátrica por VIH-1 ocurre, principalmente, por transmisión perinatal madre-hijo, también llamada transmisión vertical. En este documento discutiremos las diferentes rutas y momentos en los cuales se puede producir el contagio, así como las estrategias actuales para su reducción y/o control. Abundaremos en el uso de la terapia anti-retroviral profiláctica en la mujer embarazada infectada con VIH-1, así como la repercusión económica que ello tiene para la población de la Región de América Latina y el Caribe. Discutiremos la importancia de la forma de alumbramiento y su relación con la transmisión madre-hijo del VIH-1, así como el papel que juega la lactancia materna en la transmisión vertical. Finalmente discutiremos las estrategias epidemiológicas para la reducción del riesgo de transmisión madre-hijo del VIH-1, de las Agencias que componen el Programa Conjunto de las Naciones Unidas para el VIH/SIDA (ONUSIDA), y la Secretaría de Salud de México (SSA).

REFERENCIAS (EN ESTE ARTÍCULO)

1. ONUSIDA, AIDS Epidemic Update, December 2000.

2. Israel E, Huber D. HIV transmission through breat feeding. Technical Guidance Series No. 1. Watertown, Massachusetts Pathfinder Internationl, December 1999.

3. UNAIDS. Questions and Answers: Mother/to/Child Transmission (MTCT) of HIV. (August 5, 1999).

4. Marseille E et al. Cost-effectiveness of single dose nevirapine regimes to mothers and babies to decrease vertical HIV-1 transmission in Sub-Saharan Africa. Lancet 1999; 354(9181): 803-09.

5. Luo C. Strategies for prevention of mother-to-child transmission of HIV. Reproductive Health Matters 2000; 8(16): 144-155.

6. Guay LA et al. Intrapartum and neonatal single dose nevirapine compared to zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999; 354(9181): 795-802.

7. Preventing HIV/AIDS in Low-Resource Settings. Outlook 2001; 19(1): 2-8.

8. Giaquinto C et al. HIV: mother to child transmission, current knowledge and on-going studies. International Journal of Gynecology and Obstetrics 1998; 63(suppl. 1): S161-S165.

9. Gibb DM, Tess BH. Interventions to reduce mother-to-child transmission of HIV infection: new developments and current controversies. AIDS 1999; 13(suppl A): S93-S102.

10. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 1998; 10: 1-40.

11. Working Group on Mother-to-Child Transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America and Europe. J Acquir Immune Defic Synder Hum Retrovirol 1995; 8: 606-510.

12. De Cock KM, Fowler MG, Mercier E et al. Prevention of mother-to-child HIV transmission in resource-poor countries. JAMA 2000; 283: 1175-1182.

13. Connor EM, Sperling RS, Gelber R et al. Reductions of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 33: 1173-1180.

14. Sperling RS, Shapiro DE, Cooms RW et al. Maternal viral load, zidovudine treatment and the risk of transmission of human immnunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335: 1621-1629.

15. Temmerman M, Chomba EN, Ndinya-Achola J, Plummer FA, Coppens M, Piot P. Maternal HIV-1 infection and pregnancy outcome. Obstet Gynecol 1994; 83: 495-501.

16. Temmerman M, Nyong’o A, Bwayo J et al. Risk Factors for mother-to-child transmission of human immunodeficiency virus- 1 infection. Am J Obstet Gynecol 1995; 172:2: 700-705.

17. Gabiano C, Tovo P-A, de Martino M et al. Mother-to-child transmission of human immunodeficiency virus type 1: risk of infection and correlates of transmission. Pediatrics 1992; 90: 369-74.

18. Scherpbier HJ, Kampinga GA, Boer K. Prognostic factors for vertical HIV transmission. In: Proceedings of the eighth international conference on AIDS/third STD world congress, Amsterdam, The Netherlands, July 19-24, 1992. Amsterdam: International Conference on AIDS/STD World Congress, 1992.

19. Blanche S, Rouzioux C, Guihard Moscato M-L et al. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. N Engl J Med 1989; 320: 1634-48.

20. Lindgren S, Anzen B, Bohlin A-B, Lidman K. HIV and childbearing: clinical outcome and aspects of mother-to-infant transmission. AIDS 1991; 5: 1111-6.

21. Goedert JJ, Mendez H, Drummond JE et al. Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp 120. Lancet 1989; 2: 1351-4.

22. Mofenson L. Antiretroviral therapy and interruption of HIV perinatal transmission. Immunol Allergy Clin North Am 1998; 18: 441-463.

23. Newell ML. Mechanisms and timing of mother to child transmission of HIV-1. AIDS 1998; 12: 831-837.

24. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992; 327: 1246-1247.

25. Kuhn L, Abrams EJ, Chincilla M, Tsai WY, Thea DM. For theNew York City Perinatal Study Group, Sensitivity og HIV-1 DNA polymerase chain Reaction in the neonatal period. AIDS 1996; 10: 1181-1182.

26. Kalish LA, Pitt J, Lew J et al. Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 infection on the basis of age at first possible culture. J infect Dis 1997; 175: 712-715.

27. Shearer WT, Quinn TC, LaRussa P et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997; 336: 1337-1342.

28. Steketee RW, Abrams EJ, Thea DM et al. Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. J Infec Dis l997; 175: 707-711.

29. The European Collaborative Study. Cesarean Section and Risk of vertical transmission of HIV-1 infection. Lancet 1994; 343: 1464-1467.

30. Mandelbort L, LeChenadec J, Berrebi A, Bongain A et al. Perinatal HIV-1 transmission. JAMA 1998; 280: 55-60.

31. Kind C, Rudin C, Siegrist CA et al. Prevention of Vertical HIV Transmission. AIDS l998; 12: 205-210.

32. The European Mode of Delivery Collaboration. Ellective Cesarean Section versus Vaginal Delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet 1999; 353: 1035-1039.

33. Kuhn L, Abrams EJ, Matherson PB et al. Timing of maternalinfant HIV transmision: association between intrapartum factors and early polymerase chain reaction results. AIDS 1997; 11: 429-435.

34. Minkoff H, Burns DN, Landesman S et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 1995; 173: 585-589.

35. Landesman SH, Kalish LA, Burns DN et al. Obstetrical Factors and the transmission of immunodeficiency virus type 1 from mother to child. N Engl J Med 1996; 334: 1617-1623.

36. Kourthys AP, Bultrerys M, Nesheim SR, Lee FK. Understanding the Timing of HIV Transmission From Mother to Infant. JAMA 2001; 285: 709-712.

37. Shaffer N, Chuachoowong R, Mock PA et al. Short Course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand. Lancet 1999; 353: 773-780.

38. Connor EM, Sperling RS, Gelber R et al. Reduction of Maternal-Infant Transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-1180.

39. A. Pascual, I Bruna, J Cerrolaza, P Moreno, J. T. Ramos, A. R. Noriega, R Delgado. Absence of maternal-fetal transmission of human immunodeficiency virus type 1 to second-trimester fetuses. Am J of Obstets and Gynecol 2000; 183: 3.

40. Gibb DM et al. Uptake of Interventions to reduce mother-tochild transmission of HIV in the United Kingdom and Ireland. AIDS 1997; 11: F53-F58.

41. Read J. Mode of delivery and vertical transmission of HIV-1: a meta analysis from fifteen prospective cohort studies (The International Perinatal HIV Group). 12th World AIDS Conference, Geneva, 28 June-3 July 1998, Abstract 23603.

42. The European Mode of Delivery Collaboration. Elective Cesarean-section versus vaginal delivery in prevention of vertical VIH-1 transmission: a randomized clinical trial. Lancet 1999; 353: 1053-1039.

43. Towers VC, Deveikis A, Asrat T, Major C et al. A Bloodless “Cesarean Section” and perinatal transmission of HIV. Am J Obstet Gynecol 1998; 179: 708-14.

44. Read JS. For The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340: 977-987.

45. Parazzini F, for the European Mode of Delivery Collaboration. Elective cesarean section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized controlled trial. Lancet 1999; 353: 1035-1039.

46. Semprini AE, Castagna C, Ravizza M et al. The incidence of complications after cesarean section in 156 HIV-positive women. AIDS 1995; 9: 913-917.

47. Read J, Kpamegan E, Tuomala R et al. Mode of delivery and postpartum morbidity among HIV-infected women: The Women and Infants Transmission Study (WITS). In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999, Chicago, Ill. Abstract 683.

48. Watts H, Mofenson L, Whitehouse J et al. Complications according to mode of delivery among HIV-positive women with CD4 counts < 500. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 684.

49. Dickover RE, Garratty EM, Herman SA et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996; 275: 599-605.

50. Biggar RJ et al. Perinatal intervention trial in Africa: effect of birth canal cleansing intervention to prevent HIV transmission. Lancet 1996; 347: 1647-1650.

51. Taha TE et al. The effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial. Br Med J 1997; 315: 216-219.

52. Hofmeyr GJ, McIntyre JA. Preventing perinatal infections (editorial). Br Med J 1997; 315: 199-200.

53. Nduati R et al. Human Immunodeficiency Virus type 1-infected cells in breast mil: association with immunosupression and vitamin A deficiency. J Infect Dis 1995; 172: 1461-1468.

54. Lewis P et al. Cell-free Human immunodeficiency virus type 1 in breast milk. J Infect Dis 1998; 177(1): 34-39.

55. Newel M-L, Gray G, Bryson YJ. Prevention of Mother-to-child transmission HIV-positive women. AIDS 1997; 11 (Suppl A): S165-S172.

56. Van de Perre P et al. Infective and anti-infective properties of breast milk from HIV-1 infected women. Lancet 1993; 341(8850): 914-8.

57. Mofenson L, Wolinsky SM. Current insights regarding vertical transmission. In: Pizzo OA, Wilfert CM (eds.) Pediatric AIDS, Edition 4. Baltimore, Williams and Wilkins 1995: 179-203.

58. Steih ER. Newborn’s factors in maternal-infant transmission of pediatric HIV-1 infection. J Nutr 1996; 126: 2632S-2636S.

59. Dunn DT et al. Risk of immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992; 340: 585-588.

60. Gary GE, McIntyre JA, Lyons SF. The effect of breastfeeding on vertical transmission of HIV-1 in Soweto, South Africa, XI International Conference on AIDS, Vancouver, 1997, Abstract THC415.

61. Van de Perre P et al. Postnatal transmission of Human immunodeficiency virus type 1 from mother to child: a prospective study in Kigali, Rwanda. N Engl J Med 1991; 325: 585-588.

62. Van de Perre P et al. Postnatal transmission of HIV-1 associated with Breast abscess. Lancet 1992; 339: 1490-1491.

63. Kambarami RA, Kowo H. The prevalence of nipple disease among breastfeeding mothers of HIV seropositive infants. Cent Afr J Med 1997; 43(1): 20-22.

64. Johestone FD. HIV and pregnancy. Br J Obstet Gynecol 1996; 103: 1148-1190.

65. Connor EM, Sperling R, Gelber R et al. Reduction of Maternal-Infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1171-1180.

66. Orloff SL, Wallingford JC, McDouglas JS. Inactivation of human immunodeficiency virus type-1 in human milk: effects of intrinsic factors in human milk and pasteurization. Journal of Human Lactation 1993; 9: 13-17.

67. Reggy A, Simonds RJ, Rogers M. Preventing perinatal HIV transmission. AIDS 1997, 11(Suppl A): S61-S67.

68. Simonds RJ et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV-1. Perinatal AIDS Collaborative Transmission Studies. AIDS 1998; 12(3): 301-308.

69. Dickover RE et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996; 275: 599-605.

70. Sperling RS et al. Maternal, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trial Group Protocol 076 Study Group. N Engl J Med 1996, 335(22): 1621-1629.

71. Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force of long-term effects of in utero exposure to zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994; 43: RR-11.

72. Simmonds RJ, Rogers M. Preventing perinatal HIV infection: How far have we come? JAMA 1996; 275: 1514-1515.

73. Gibb DM et al. Uptake of interventions to reduce mother-tochild transmission of HIV-1 in the United Kingdom and Ireland. AIDS 1997; 11: F53-F58.

74. Landers DV, Sweet RL. Reducing mother-to-infant of HIVthe door remains open. N Engl J Med 1996; 334: 1664-1665.

75. Van de Perle P et al. Zidovudine and breastfeeding. AIDS Patients Care and STDs, 1997; 11(1): 4-5.

76. Mayaux MJ et al. Acceptability and impact of zidovudine for prevention of mother-to child human immunodeficiency virus transmission in France. J Pediatr 1997; 131(2): 857-862.

77. Centers for Disease Control and Prevention. AIDS among children-United States. 1996, MMWR 1996; 45: 1005- 1010.

78. Bessinger R et al. Pregnancy is not associated with the progression of HIV disease in women attending an HIV outpatient program. Am J Epidemiol 1998; 147(5): 434-440.

79. Brisson Y. Perinatal HIV-1 transmission: recent advances and therapeutic interventions. AIDS 1996; 10(Suppl 3): S33-S42.

80. Ficus SA et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban countries. JAMA 1996; 275(19): 1483-1488.

81. Culnane M et al. For The Pediatric AIDS Clinical Trial Group Protocol 219/076 Teams. Lack of long-term effect of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 1999; 281(2):151-157.

82. Withe A, Eldridge R, Andrews E and the Antiretroviral Pregnancy Registry Advisory Committee. Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry. Acta Pediatr 1997, Suppl 421: 86-88.

83. Connor E et al. Protocol 076 and 219 study group. Long-term effect of ZDV exposure among uninfected infants born HIV infected mothers in PACTG Protocol 076. 35th Interscience Conference on antimicrobial agents and chemotherapy, New Orleans, 1996, Abstract 111.

84. Ayers KM et al. Nonclinical toxicology studies with zidovudine: genetic toxicity test and carcinogenicity bioassay in mice and rats. Fundam Appl Toxicol 1996; 32: 148-158.

85. Olivero OA et al. AZT is a genotoxic transplacental carcinogen in animal models. JAIDS 1997, 14: A29 Abstract 52.

86. Eastman PS et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatrics AIDS Clinical Trial Group Protocol 076. J Infect Disc 1998; 177(3): 557-564.

87. McIntosh K. Antiretroviral resistance and HIV vertical transmission. Acta Pediatr 1997, Suppl 421: 29-32.

88. Srinivas RV et al. Development of zidovudine-resistant HIV genotypes following postnatal prophylaxis in perinatally infected infants. AIDS 1996; 10(7): 795-796.

89. Frenkel LM et al. Analysis of maternal components of AIDS Clinical Trial Group 076 zidovudine regimen in the prevention of mother to infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997; 175: 971-974.

90. Simpson BJ, Shapiro ED, Andiman WA. Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 145-152.

91. Shaffer N et al. Short course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized control trial. Lancet 1999; 353: 773-780.

92. Dabid F et al. For the DITRAME Study Group. 6-month efficacy, tolerance and acceptability of short regimen of oral zidovudine to reduce vertical transmission of HIV breastfed children in Cote d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicenter trial. Lancet 1999; 353: 786-92.

93. Wiktor S et al. Short Course oral zidovudine for prevention of mother to child transmission of HIV-1 in Abidjan, Cote d’Ivoire: a randomized trial. Lancet 1999; 353: 781-785.

94. Katlama C, Ingrand D, Loveday C et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviralnaive patients. JAMA 1996; 276: 118-125.

95. Moodley J, Moodley K, Coovadia PH et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when administered with zidovudine in human immunodeficiency virus type-1 infected pregnant women and their offspring. J Infect Dis 1988; 178: 1327-1333.

96. Brockelhurst P. Interventions for reducing mother-to-child transmission HIV infection (Cochrane Review) In: The Cochrane Library. Oxford: Update Softwares.

97. Blanche et al. Zidovudine-lamivudine for prevention of mother to child HIV-1 transmission. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago. Abstract 267, 1999.

98. Agence Nationale de Reserches sur le SIDA. Gradation des Effects Indesirables: Redaction d’un Protcole Don’t l’ANRS Est Promoteur. Paris, France: Agence Nationale de Reserches sur le SIDA; 1996.

99. Adjordlo-Johnson G, De Cock KM, Ekpini E et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272: 462-466.

100. Andreasson PA, Días F, Naucler A, Andersson S, Biberfeld G. A prospective study of vertical transmission of HIV-2 in Bissau, Guinea Bissau. AIDS 1993; 7: 989-993.

101. Morgan G, Wilkins HA, Pepin J, Ousman J, Brewster D, Whittle H et al. AIDS following mother-to-child transmission of HIV-2. AIDS 1990; 4: 879-882.

102. WHO/UNAIDS. HIV and infant feeding. Guidelines for Decisionmakers. Geneva: WHO, UNAIDS. June 1999.

103. Rouzioux C, Costagliola D, Burgand M et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model.

104. Prevención del contagio. Promoción de la Salud Reproductiva. La Respuesta del FNUAP al VIH/SIDA. Fondo de Población de las Naciones Unidas ISBN 0-89714-607-7 S/3.000/2001).

105. Joint United Nations Programme on Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. Economic and Social Council, Substantive Session of 2001, Geneva, 2-27 July 2001.